Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity

被引:19
作者
Troost, Esther G. C. [1 ]
Bussink, Johan [1 ]
Slootweg, Piet J. [2 ]
Peeters, Wenny J. M. [1 ]
Merkx, Matthias A. W. [3 ]
van der Kogel, Albert J. [1 ]
Oyen, Wim J. G. [4 ]
Kaanders, Johannes H. A. M. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Maxillofacial Surg, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词
F-18-fluorothymidine PET; proliferation; head and neck cancer; immunohistochemistry; iododeoxyuridine; thymidine kinase; CYTOSOLIC THYMIDINE KINASE; F-18-FLT PET; NECK-CANCER; IMAGING PROLIFERATION; NUCLEAR ANTIGEN; IN-VIVO; RADIOTHERAPY; HEAD; REPOPULATION; THERAPY;
D O I
10.2967/jnumed.109.071910
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of F-18-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate F-18-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Methods: Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an F-18-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. F-18-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUVmean] and maximum standardized uptake value [SUVmax]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was visually and semiquantitatively assessed. Results: All primary tumors were identified with F-18-FLT PET but with a large range in tracer uptake (mean SUVmax, 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUVmean and SUVmax, but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor F-18-FLT uptake. Conclusion: The current study demonstrated only a weak correlation between F-18-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 50 条
[1]   Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice [J].
Yue, Jin-Bo ;
Yang, Jia ;
Liu, Jing ;
Lee, Jason ;
Cabrera, Alvin R. ;
Sun, Xin-Dong ;
Bai, Guang-Hui ;
Li, Yu-Hui ;
Yu, Jin-Ming .
RADIOTHERAPY AND ONCOLOGY, 2014, 111 (03) :475-481
[2]   Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements [J].
Hatt, Mathieu ;
Rest, Catherine Cheze-Le ;
Aboagye, Eric O. ;
Kenny, Laura M. ;
Rosso, Lula ;
Turkheimer, Federico E. ;
Albarghach, Nidal M. ;
Metges, Jean-Philippe ;
Pradier, Olivier ;
Visvikis, Dimitris .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) :1368-1376
[3]   In response to "Histopathologic validation of 3′-deoxy-3′-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice" [J].
Troost, Esther G. C. ;
Hoeben, Bianca A. W. ;
Laverman, Peter ;
Bussink, Jan ;
Oyen, Wim J. G. .
RADIOTHERAPY AND ONCOLOGY, 2015, 114 (03) :417-418
[4]   Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer [J].
Kishino, Takehito ;
Hoshikawa, Hiroshi ;
Nishiyama, Yoshihiro ;
Yamamoto, Yuka ;
Mori, Nozomu .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (10) :1521-1527
[5]   Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET [J].
Waldherr, C ;
Mellinghoff, IK ;
Tran, C ;
Halpern, BS ;
Rozengurt, N ;
Safaei, A ;
Weber, WA ;
Stout, D ;
Satyamurthy, N ;
Barrio, J ;
Phelps, ME ;
Silverman, DH ;
Sawyers, CL ;
Czernin, J .
JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (01) :114-120
[6]   Prognostic value of 3′-Deoxy-3′-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas [J].
Zhao, Fen ;
Cui, Yunfeng ;
Li, Minghuan ;
Fu, Zheng ;
Chen, Zhaoqiu ;
Kong, Li ;
Yang, Guoren ;
Yu, Jinming .
NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (08) :710-715
[7]   18F-FDG or 3′-Deoxy-3′-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma [J].
Wondergem, Marielle J. ;
Rizvi, Saiyada N. F. ;
Jauw, Yvonne ;
Hoekstra, Otto S. ;
Hoetjes, Nikie ;
van de Ven, Peter M. ;
Boellaard, Ronald ;
Chamuleau, Martine E. D. ;
Cillessen, Saskia A. G. M. ;
Regelink, Josien C. ;
Zweegman, Sonja ;
Zijlstra, Josee M. .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) :216-221
[8]   3′-Deoxy-3′-[18F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer [J].
Chen, Haojun ;
Li, Yimin ;
Wu, Hua ;
Sun, Long ;
Lin, Qin ;
Zhao, Long ;
An, Hanxiang .
STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (02) :141-152
[9]   A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma [J].
Herrmann, Ken ;
Buck, Andreas K. ;
Schuster, Tibor ;
Rudelius, Martina ;
Wester, Hans-Juergen ;
Graf, Nicolas ;
Scheuerer, Christine ;
Peschel, Christian ;
Schwaiger, Markus ;
Dechow, Tobias ;
Keller, Ulrich .
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) :1898-1902
[10]   Early Determination of Prognosis by Interim 3′-Deoxy-3′-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma [J].
Lee, Hyewon ;
Kim, Seok-ki ;
Kim, Yong-Il ;
Kim, Tae Sung ;
Kang, Se Hun ;
Park, Weon Seo ;
Yun, Tak ;
Eom, Hyeon-Seok .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) :216-222